Sutro has published the first phase clinical results of its ADC products against ovarian cancer

Sutro biopharma, located in San Francisco, California, USA, is a research, development and production enterprise of tumor drugs whose products are in clinical stage The company today released data on the safety and potential anticancer activity of stro-002, an anti folate alpha receptor antibody drug conjugate, in a preclinical xenotransplantation (PDX) model derived from patients with endometrial cancer The ongoing phase I trial is an open label, multicenter, incremental dose study to determine the MTD of stro-002, evaluate the safety, tolerability, and preliminary antitumor activity of stro-002, and find the recommended phase II dose So far, the company has applied stro-002 to 13 patients in phase I study, but has not found the maximum tolerable dose (MTD) Two of the patients received 6 mg / kg of the drug and showed normal performance during the DLT observation period The company will increase its usage in the future So far, there is no DLT and infusion response in these patients who have received a lot of treatment Preliminary evidence of antitumor activity was observed in patients with partial response confirmed by the RECIST 1.1 standard (Biovalley / BIOON Com) original source: SURTO official website